Genocea Biosciences (NASDAQ:GNCA) Rating Lowered to Hold at Stifel Nicolaus

Genocea Biosciences (NASDAQ:GNCAGet Rating) was downgraded by stock analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, The Fly reports.

A number of other brokerages have also weighed in on GNCA. Robert W. Baird decreased their price target on shares of Genocea Biosciences from $8.00 to $3.00 in a research note on Monday, April 11th. StockNews.com started coverage on shares of Genocea Biosciences in a research note on Wednesday. They issued a “sell” rating on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, Genocea Biosciences currently has an average rating of “Hold” and an average price target of $2.63.

NASDAQ:GNCA opened at $0.41 on Friday. Genocea Biosciences has a 52 week low of $0.30 and a 52 week high of $2.76. The company has a quick ratio of 2.24, a current ratio of 2.24 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $23.96 million, a PE ratio of -0.67 and a beta of 1.45. The stock’s 50-day moving average price is $0.95 and its 200-day moving average price is $1.17.

Genocea Biosciences (NASDAQ:GNCAGet Rating) last posted its earnings results on Thursday, March 10th. The biotechnology company reported ($0.19) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.01). During the same quarter in the previous year, the business posted ($0.18) earnings per share. Sell-side analysts expect that Genocea Biosciences will post -0.76 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Acadian Asset Management LLC purchased a new position in Genocea Biosciences in the 4th quarter worth approximately $25,000. Renaissance Technologies LLC purchased a new position in Genocea Biosciences in the 4th quarter worth approximately $32,000. Commonwealth Equity Services LLC lifted its stake in Genocea Biosciences by 49.4% in the 4th quarter. Commonwealth Equity Services LLC now owns 31,981 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 10,576 shares in the last quarter. Morgan Stanley lifted its stake in Genocea Biosciences by 197.5% in the 2nd quarter. Morgan Stanley now owns 16,504 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 10,957 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in Genocea Biosciences by 25.4% in the 4th quarter. Northern Trust Corp now owns 70,837 shares of the biotechnology company’s stock worth $82,000 after purchasing an additional 14,368 shares in the last quarter. 59.25% of the stock is currently owned by institutional investors and hedge funds.

Genocea Biosciences Company Profile (Get Rating)

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.

See Also

The Fly logo

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.